Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Nov 30;14(1):7866.
doi: 10.1038/s41467-023-42848-5.

How carvedilol does not activate β2-adrenoceptors

Robert J Lefkowitz  1   2   3 , Howard A Rockman  4 , Paul J Shim  5 , Samuel Liu  5 , Seungkirl Ahn  5 , Biswaranjan Pani  5 , Sudarshan Rajagopal  5   6 , Sudha K Shenoy  5 , Michel Bouvier  7 , Jeffrey L Benovic  8 , Stephen B Liggett  9 , Robert R Ruffolo  10 , Michael R Bristow  11 , Milton Packer  12   13
Affiliations
Comment

How carvedilol does not activate β2-adrenoceptors

Robert J Lefkowitz et al. Nat Commun. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Comment in

  • Reply to: How carvedilol does not activate β2-adrenoceptors.
    Kostenis E, Gomeza J, Miess-Tanneberg E, Blum NK, Benkel T, Chevigné A, Hoffmann C, Kolb P, Nikolaev V, Waldhoer M, Szpakowska M, Inoue A, Schulz S. Kostenis E, et al. Nat Commun. 2023 Nov 30;14(1):7867. doi: 10.1038/s41467-023-42849-4. Nat Commun. 2023. PMID: 38036502 Free PMC article. No abstract available.

Comment on

  • How Carvedilol activates β2-adrenoceptors.
    Benkel T, Zimmermann M, Zeiner J, Bravo S, Merten N, Lim VJY, Matthees ESF, Drube J, Miess-Tanneberg E, Malan D, Szpakowska M, Monteleone S, Grimes J, Koszegi Z, Lanoiselée Y, O'Brien S, Pavlaki N, Dobberstein N, Inoue A, Nikolaev V, Calebiro D, Chevigné A, Sasse P, Schulz S, Hoffmann C, Kolb P, Waldhoer M, Simon K, Gomeza J, Kostenis E. Benkel T, et al. Nat Commun. 2022 Nov 19;13(1):7109. doi: 10.1038/s41467-022-34765-w. Nat Commun. 2022. PMID: 36402762 Free PMC article.

References

    1. Bristow MR. beta-adrenergic receptor blockade in chronic heart failure. Circulation. 2000;101:558–569. doi: 10.1161/01.CIR.101.5.558. - DOI - PubMed
    1. Packer M. Beta-adrenergic blockade in chronic heart failure: principles, progress, and practice. Prog. Cardiovasc. Dis. 1998;41:39–52. doi: 10.1016/S0033-0620(98)80030-3. - DOI - PubMed
    1. Packer M, et al. Effect of carvedilol on survival in severe chronic heart failure. N. Engl. J. Med. 2001;344:1651–1658. doi: 10.1056/NEJM200105313442201. - DOI - PubMed
    1. Ruffolo RR, Feuerstein GZ. Carvedilol case history: the discovery and development of the first beta-blocker for the treatment of congestive heart failure. Expert Opin. Drug Discov. 2006;1:85–89. doi: 10.1517/17460441.1.1.85. - DOI - PubMed
    1. The Xamoterol in Severe Heart Failure Study Group. Xamoterol in severe heart failure. Lancet. 1990;336:1–6. doi: 10.1016/0140-6736(90)91517-E. - DOI - PubMed

MeSH terms